HCM
HEALTHCAREHUTCHMED (China) Ltd
$13.43+0.13 (+0.98%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving HCM Today?
No stock-specific AI insight has been generated for HCM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$12.82$19.50
$13.43
Fundamentals
Market Cap$2.3B
P/E Ratio5.1
EPS$2.65
Dividend Yield—
Dividend / Share—
ROE0.5%
Profit Margin0.8%
Debt / Equity—
Trading
Volume16K
Avg Volume (10D)—
Shares Outstanding171.9M
HCM News
20 articles- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online ViewingYahoo Finance·Apr 29, 2026
- HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaYahoo Finance·Apr 29, 2026
- HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB ConferenceMarketbeat·Apr 29, 2026
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026Yahoo Finance·Apr 23, 2026
- HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026GlobeNewswire Inc.·Apr 9, 2026
- Should You Be Adding HUTCHMED (China) (LON:HCM) To Your Watchlist Today?Yahoo Finance·Mar 31, 2026
- HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in ChinaYahoo Finance·Mar 23, 2026
- HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ...Yahoo Finance·Mar 12, 2026
- Sector Update: Health Care Stocks Decline Premarket MondayYahoo Finance·Mar 9, 2026
- HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in ChinaYahoo Finance·Mar 9, 2026
- Hutchmed price target lowered to $21 from $22 at BofAYahoo Finance·Mar 7, 2026
- Intended Retirement of Independent Non-executive Director and changes of composition of board committeesYahoo Finance·Mar 6, 2026
- HUTCHMED H2 Earnings Call HighlightsMarketbeat·Mar 6, 2026
- HUTCHMED Reports 2025 Full Year Results and Business UpdatesYahoo Finance·Mar 5, 2026
- HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid TumorsYahoo Finance·Mar 4, 2026
- HUTCHMED to Announce 2025 Final ResultsYahoo Finance·Feb 6, 2026
- Paycom Software, Inc. (PAYC): A Bull Case TheoryYahoo Finance·Feb 3, 2026
- HUTCHMED Highlights Publication of Phase III SACHI Results in The LancetYahoo Finance·Jan 14, 2026
- Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should KnowYahoo Finance·Jan 7, 2026
- HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in ChinaYahoo Finance·Jan 7, 2026
All 20 articles loaded
Price Data
Open$13.49
Previous Close$13.30
Day High$13.50
Day Low$12.82
52 Week High$19.50
52 Week Low$12.82
52-Week Range
$12.82$19.50
$13.43
Fundamentals
Market Cap$2.3B
P/E Ratio5.1
EPS$2.65
Dividend Yield—
Dividend / Share—
ROE0.5%
Profit Margin0.8%
Debt / Equity—
Trading
Volume16K
Avg Volume (10D)—
Shares Outstanding171.9M
About HUTCHMED (China) Ltd
HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—